X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Canada’s Valeant buys Salix for $11bn

Yuvraj_pawp by Yuvraj_pawp
2nd April 2015
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Canada-based Valeant Pharmaceuticals International has completed the acquisition of US-based Salix Pharmaceuticals for around $11bn.

 

Under the deal, Valeant has acquired all outstanding common stock of Salix for $173.00 per share in cash.

 

Based in Raleigh of North Carolina, Salix develops and markets prescription pharmaceutical products and medical devices to treat gastrointestinal diseases.

 

Both firms first entered the deal in February this year, when Valeant agreed to pay $158.00 per Salix share or an enterprise value of $14.5bn. “This revised offer provides Salix shareholders with all-cash at a significant premium and the certainty to close by 1 April.”

 

In March, Valeant increased its offer price for Salix, as specialty healthcare firm Endo Internationl proposed to pay $175 per Salix share.

 

Under the amendment, Valeant agreed to pay an increased price of $173.00 per share to Salix over the original price of $158.00 per share, adding around additional $1bn cash to Salix stockholders.

 

At the time of amendment of agreement, Valeant Pharmaceuticals International chairman and CEO Michael Pearson said: “This revised offer provides Salix shareholders with all-cash at a significant premium and the certainty to close by 1 April.”

 

Salix Pharmaceuticals board chairman and acting CEO Thomas D’Alonzo said: “We are pleased that the enhanced offer price recognises the value of Salix as the leading gastrointestinal specialty pharmaceutical company and delivers to our stockholders all cash consideration in the near future.”

 

Holding a significant share in gastrointestinal market, Salix produces 22 products, including prescription brands.

 

Salix produces gastroenterology treatments such as Xifaxan (rifaximin) 550mg, Ruconest (C1 esterase inhibitor [recombinant]), Apriso (mesalamine), Uceris (budesonide) extended release tablets and Relistor (methylnaltrexone bromide).

Tags: America
Previous Post

Micromeritics Announces Instrument Grant to the University of Georgia

Next Post

RSSL Doubles QP Course Dates Following Increased Demand

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

RSSL Doubles QP Course Dates Following Increased Demand

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In